TP53 and esophageal squamous cell carcinoma: A phase Ib/II clinical trial showed that when P53 is inhibited with APR-246, it can increase the consumption of intracellular glutathione, dramatically decrease SCL7A11 expression, and induce ferroptosis in ESCC.